收藏切换
Progress in targeted drug therapy for pediatric chronic myelogenous leukemia
收藏切换
Zhiwei XIE, Ningling WANG*, Kunlong ZHANG, Jinhua CHU, Linhai YANG
World Clinical Drug | 2026, 47(1) : 1 - 6
Less
收藏切换
World Clinical Drug | 2026, 47(1): 1-6
• Topic •
Progress in targeted drug therapy for pediatric chronic myelogenous leukemia
Full
Zhiwei XIE, Ningling WANG*, Kunlong ZHANG, Jinhua CHU, Linhai YANG
Affiliations
  • Department of Pediatrics, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China
Published: 2026-01-10 doi: 10.13683/j.wph.2026.01.001
Outline
收藏切换

Pediatric chronic myelogenous leukemia(CML), a malignant hematopoietic stem cell disease driven by the BCR/ABL fusion gene. The emergence of tyrosine kinase inhibitor(TKI) has significantly improved long-term survival rates in children with CML, marking a milestone in its therapeutic history. However, TKI may exert long-term effects on pediatric growth and development, necessitating careful consideration of lifelong treatment tolerance and quality of life. The status of the second-generation TKI, dasatinib and nilotinib, in the first-line treatment of pediatric CML has been further clarified. The long-term value of imatinib has been precisely evaluated in specific populations. The novel agents like asciminib, which offer new avenues to overcome resistance. This review systematically summarized key recent progress in targeted therapy for pediatric CML, deeply analyzed the efficacy and safety profiles of each TKI generation,discussed individualized treatment selection strategies, and envisioned future directions guided by precision medicine and functional cure.

pediatric chronic myeloid leukemia  /  BCR/ABL fusion gene  /  tyrosine kinase inhibitor  /  allosteric inhibitor  /  treatment discontinuation  /  individualized therapy
谢志伟, 王宁玲, 张坤龙, 储金华, 杨林海. 儿童慢性髓细胞性白血病靶向药物治疗进展. 世界临床药物, 2026 , 47 (1) : 1 -6 . DOI: 10.13683/j.wph.2026.01.001
Zhiwei XIE, Ningling WANG, Kunlong ZHANG, Jinhua CHU, Linhai YANG. Progress in targeted drug therapy for pediatric chronic myelogenous leukemia[J]. World Clinical Drug, 2026 , 47 (1) : 1 -6 . DOI: 10.13683/j.wph.2026.01.001
Year 2026 volume 47 Issue 1
52
12
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.01.001
  • Receive Date:2025-11-28
  • Online Date:2026-11-05
  • Published:2026-01-10
Article Data
Affiliations
History
  • Received:2025-11-28
Affiliations
    Department of Pediatrics, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.01.001
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT